Participants in the study will be randomly assigned to receive either the study medication or a placebo. During the 52-week period, the study will monitor how well the treatment works in preventing a flare, which is a sudden increase in disease symptoms or activity. The research will also look at how the medication affects the need for other treatments, such as glucocorticoids or immunomodulators, which are drugs used to lower immune system activity.

The research will examine how the body processes the medication, which is known as pharmacokinetics, and how the drug affects the body’s biological functions, known as pharmacodynamics. During the study, researchers will also monitor the safety and how well the body tolerates the treatment. This involves checking how the drug impacts CD20+ B cells, which are a specific type of white blood cell involved in the immune response.

Participants will be monitored over a period of time to see how the medication affects the symptoms of the disease. The study will track how the drug behaves in the blood and observe any changes in the body’s reaction to the treatment. This includes monitoring for any side effects or changes in health indicators to ensure the medication is being used safely in children and teenagers.

The purpose of this research is to determine if the new imaging tracer can work as well as or better than the current standard method in detecting and evaluating inflammatory conditions. The study will look at how well each tracer can identify the source of unexplained fever and inflammation, assess the extent of IgG4-related disease (a condition that can affect multiple organs), and distinguish between inflammatory and mechanical back pain in patients with spine problems.

During the study, participants will receive an intravenous injection of the imaging tracer before undergoing the PET/CT scan. Some participants may need to have two scans, particularly those with spine conditions who will be evaluated before and after three months of treatment. The maximum amount of tracer used for each scan will be 100 MBq, with a total maximum dose of 550 MBq over the entire study period.

The purpose of the study is to evaluate how effective inebilizumab is in reducing the risk of a disease flare, which is a sudden worsening of symptoms, in patients with IgG4-related disease. Participants in the study will receive either the medication or a placebo, and the study will follow them over a period to see how well the treatment works in preventing flares. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the effectiveness of the treatment. The study aims to provide valuable information on whether inebilizumab can be a safe and effective treatment option for managing IgG4-related disease and reducing the frequency of flares. This research could potentially lead to better treatment options for those affected by this condition.

Participants in the study will receive either abatacept or a placebo. The study will last for a total of 48 weeks, during which time the effects of the treatment will be monitored. Abatacept is administered through a method called subcutaneous use, which means it is given as an injection under the skin. The goal is to determine if abatacept can help prevent the recurrence of symptoms in patients with IgG4-related disease.

Throughout the study, participants will be regularly assessed to track their progress and any changes in their condition. The trial aims to provide valuable information on whether abatacept can be a beneficial treatment option for those suffering from IgG4-related disease, potentially offering a new way to manage this condition and improve patient outcomes.

Participants in the study will receive either Obexelimab or a placebo, which is a solution that looks like the treatment but does not contain the active medicine. The study will last for about a year, during which participants will receive weekly injections. The study aims to see if Obexelimab can help prevent flare-ups of the disease, which are times when symptoms get worse.

Throughout the study, the safety and tolerability of Obexelimab will be closely monitored. This means that researchers will keep track of any side effects or health changes that occur. The study will also look at how often flare-ups happen and how much additional treatment is needed to manage them. Participants will have regular check-ups to assess their health and the effects of the treatment.

The purpose of this study is to examine the safety and effectiveness of filgotinib in patients whose symptoms have not improved with standard treatments. Participants in the study will receive either Jyseleca 100 mg or Jyseleca 200 mg film-coated tablets, which contain the active substance filgotinib. The study will last for a period of up to 26 weeks, during which participants will take the medication orally. Some participants may receive a placebo instead of the active medication. Throughout the study, participants will be monitored to assess how well the medication is working and to check for any side effects.

By participating in this study, researchers hope to gather valuable information about the potential benefits and risks of using filgotinib for treating these rare inflammatory diseases. The findings from this study could help improve treatment options for patients with these conditions in the future.